Well, Now: What It’s Really Like to Take Ozempic
Slate Books
Slate Podcasts
3.8 • 546 Ratings
🗓️ 2 October 2024
⏱️ 49 minutes
🧾️ Download transcript
Summary
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to Well Now Slate's podcast on health and wellness. I'm Maya Feller. |
| 0:10.6 | And I'm Kavita Patel. It has been years since the FDA approved Ozembic and other similar drugs in the GLP1 class for chronic weight management and chronic disease. |
| 0:22.4 | Maya, I feel like we're still talking about it nonstop. |
| 0:26.3 | Kavita, I couldn't agree more. |
| 0:27.7 | It is the conversation of the moment and continues to be. |
| 0:31.0 | GLP1 drugs like OZempec and Wagoe, which are the same thing, have completely changed |
| 0:35.7 | the conversation about weight loss. |
| 0:37.7 | While these drugs haven't been used to treat obesity for long compared to other drugs, |
| 0:42.7 | the results we're seeing so far cannot be ignored. |
| 0:46.2 | For example, in clinical trials, people taking OZEPBIC lost nearly 15% of their body weight |
| 0:52.5 | after a little over a year taking the drug. |
| 0:55.3 | Those taking the placebo only lost 2.4%. |
| 0:58.4 | Other studies have shown nearly 90% of patients lost at least 5% of their body weight |
| 1:04.6 | within the first six months of taking a GLP1 drug. |
| 1:09.2 | That's the best results we've seen so far |
| 1:11.6 | of any weight loss drug. |
| 1:13.7 | Not only that, recent trials have found |
| 1:15.7 | that OZemPEC is highly effective |
| 1:17.7 | in preventing adverse cardiovascular events, |
| 1:20.1 | such as heart attacks, along with other chronic diseases. |
| 1:23.3 | Sounds amazing, right, Maya? |
| 1:25.3 | Yeah, I mean, it sounds amazing, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Slate Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Slate Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.

